Data from the GARNET trial with the anti-PD-1 monoclonal antibody dostarlimab, which blocks interaction with the programmed death ligands PD-L1 and -L2, have led to the approval of dostarlimab monotherapy by the Food and Drug Administration (FDA) in the United States to treat dMMR recurrent or advanced endometrial cancer that has progressed on platinum-containing regimens82 (Figure 6). This evidence concerns the gene PDCD1 and endometrial cancer.